Von Hippel–Lindau disease
Rare genetic disorder causing tumors in multiple organs
von Hippel–Lindau disease | |
---|---|
![]() | |
Synonyms | Familial cerebello-retinal angiomatosis, VHL syndrome |
Pronounce | N/A |
Field | N/A |
Symptoms | Headaches, dizziness, visual disturbances, limb weakness, balance problems, hypertension |
Complications | Vision loss, hearing impairment, renal failure, metastatic cancer, neurological deficits |
Onset | Typically young adulthood (20–40 years) |
Duration | Lifelong |
Types | N/A |
Causes | Mutation in the VHL tumor suppressor gene on chromosome 3p25.3 |
Risks | Family history, autosomal dominant inheritance |
Diagnosis | Genetic testing, imaging (MRI, CT), ophthalmologic examination |
Differential diagnosis | Neurofibromatosis type 2, multiple endocrine neoplasia (MEN), polycystic kidney disease |
Prevention | Genetic counseling, regular surveillance screenings |
Treatment | Surgical removal of tumors, radiation therapy, targeted medical therapies |
Medication | Antihypertensives, targeted therapy for associated malignancies |
Prognosis | Variable; lifelong management required, favorable with early detection and treatment |
Frequency | 1 in 36,000 individuals worldwide |
Deaths | Primarily due to complications such as metastatic cancer or renal failure |
Von Hippel–Lindau disease (VHL disease) is a rare, autosomal dominant genetic disorder characterized by the formation of tumors and fluid-filled cysts in multiple organs throughout the body. Tumors commonly occur in the central nervous system, kidneys, pancreas, adrenal glands, and eyes.
Signs and symptoms[edit | edit source]

Symptoms of VHL disease depend on tumor location, size, and organ involvement. Common presentations include:
- Neurological symptoms:
- Headaches
- Dizziness
- Problems with balance and walking (ataxia)
- Limb weakness and numbness
- Hearing impairment (due to endolymphatic sac tumors)
- Visual symptoms:
- Vision loss or blurring
- Retinal detachment
- Visual disturbances due to retinal hemangioblastoma
- Systemic symptoms:
- High blood pressure (hypertension) from adrenal tumors (pheochromocytoma)
- Abdominal pain and pancreatic dysfunction from pancreatic cysts or tumors
- Hematuria (blood in urine), flank pain, or renal dysfunction from renal cell carcinoma
Associated conditions[edit | edit source]
VHL disease predisposes patients to develop multiple tumor types, including:
- Hemangioblastomas (vascular tumors affecting the brain, spinal cord, and retina)
- Retinal hemangioblastoma (formerly called retinal angiomas)
- Renal cell carcinoma
- Pheochromocytoma (adrenal gland tumors causing high blood pressure)
- Pancreatic cysts and serous cystadenomas
- Endolymphatic sac tumor (rare inner-ear tumors causing hearing and balance issues)
- Bilateral papillary cystadenomas of the epididymis (men) or the broad ligament of the uterus (women)
Genetics[edit | edit source]
Von Hippel–Lindau disease results from a mutation in the VHL tumor suppressor gene located on the short arm of chromosome 3 (3p25.3). The disease follows an autosomal dominant inheritance pattern, meaning an affected individual has a 50% chance of passing the mutation to offspring.
The VHL gene normally functions to suppress abnormal cell growth by regulating cellular oxygen sensing. Mutation or deletion of this gene leads to uncontrolled cellular proliferation and tumor formation.
Diagnosis[edit | edit source]
Diagnosis is established through clinical criteria, family history, and genetic testing:
- Clinical evaluation: Detailed neurological, ophthalmological, and systemic examinations
- Imaging studies:
- MRI (brain, spine) to identify hemangioblastomas
- CT/MRI abdomen to evaluate kidneys, pancreas, and adrenal glands
- Genetic testing: Confirms VHL gene mutation, guides familial screening
Differential diagnosis[edit | edit source]
Conditions that must be distinguished from VHL disease include:
- Neurofibromatosis type 2 (bilateral vestibular schwannomas)
- Multiple endocrine neoplasia (MEN) syndromes
- Polycystic kidney disease
- Tuberous sclerosis complex
Management[edit | edit source]
There is no cure for VHL disease; management is focused on early detection, monitoring, and prompt treatment of tumors:
- Surgical removal of symptomatic tumors or tumors at risk of malignancy
- Radiation therapy for inaccessible or recurrent central nervous system tumors
- Medical management: Control of hypertension (particularly due to pheochromocytomas), targeted therapies for renal cell carcinoma
- Regular surveillance screenings:
- Annual ophthalmologic examinations for retinal hemangioblastomas
- Periodic MRI scans of brain and spine
- Routine screening of kidneys, pancreas, and adrenal glands through imaging and laboratory tests
Prognosis[edit | edit source]
Prognosis depends on timely diagnosis, effective tumor management, and lifelong surveillance. With early detection and intervention, patients can have relatively normal life expectancy. Delayed diagnosis or inadequate management increases risk of severe complications, including vision loss, neurological deficits, metastatic renal cell carcinoma, and premature death.
Epidemiology[edit | edit source]
Von Hippel–Lindau disease is rare, with an estimated incidence of approximately 1 in 36,000 individuals globally. It affects men and women equally and typically becomes clinically apparent in early adulthood, though age of onset can vary widely.
History[edit | edit source]
VHL disease is named after ophthalmologist Eugen von Hippel, who first described retinal hemangioblastomas in 1904, and neuropathologist Arvid Lindau, who detailed central nervous system involvement and familial inheritance in 1927.
Research[edit | edit source]
Current research is focused on:
- Improved genetic and molecular characterization of VHL mutations
- Novel targeted therapies, including drugs targeting hypoxia-inducible factors (HIF) regulated by VHL
- Gene therapy approaches to correct VHL gene defects
See also[edit | edit source]
External links[edit | edit source]
- VHL Disease – Genetic and Rare Diseases Information Center (GARD)
- VHL Alliance – Patient Advocacy Group
- Von Hippel–Lindau Disease – National Cancer Institute
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD